Press Releases

PDA is pleased to announce the results of the 2013 Board of Directors and Officers election. The elected candidates will fill their term beginning on January 1, 2012. Thank you to all who voted!

PDA is pleased to announce the results of the 2013 Board of Directors election. The elected candidates will fill their term beginning on January 1, 2013. Thank you to all who voted!

PDA Technical Reports are highly valued, global technical documents prepared by member-driven Task Forces comprised of content experts, including scientists and engineers working in the pharmaceutical and biopharmaceutical industry, regulatory authorities and academia.

Bethesda, Md., October 31, 2012 – The Parenteral Drug Association (PDA) is proud to announce the founding of the PDA India Chapter, which will serve PDA members in India.

“This is the most innovative and significant member benefit ever offered by The Parenteral Drug Association (PDA),” said Richard M. Johnson, PDA President. “We have been working hard on enhancing our member value and we believe that releasing this new Technical Report Portal by the end of 2012 is a breakthrough benefit that you just don’t see anywhere.

Our industry is entering a challenging phase for the next decade in the area of pre-filled syringes & injection devices. Costs and regulatory demands exert downward pressure on our ability to introduce devices that are safe and effective. Patients and their needs continue to grow while ever more complex molecules continue to challenge our material selection. Regulatory requirements, industry experience and evolving market trends are critical considerations to ensure a complete understanding of the application of pre-filled syringes and injection devices to drug delivery.

Bethesda, Md., July 16, 2012 – St Petersburg, Russia (June 22, 2012) – The Parenteral Drug Association (PDA) and The Saint-Petersburg State Chemical-Pharmaceutical Academy (SPCPA) have signed a Memorandum of Understanding to develop a GMP and Regulatory Affairs Training Center in the area of pharmaceutical manufacturing in St. Petersburg (the Training Center).

The Parenteral Drug Association (PDA) is coordinating a critical discussion on the implementation of QbD concepts in vaccine development.Five vaccine manufacturers (GlaxoSmithKline, MedImmune, Merck, Pfizer and Sanofi Pasteur) have joined to form the CMC-VWG, with assistance from PricewaterhouseCoopers, to create a case study describing the development of the fictitious vaccine A-Vax. The goal of the workshop is to initiate a discussion of the case study and to provide a review of the QbD approaches employed for the development of A-Vax.